European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers

Plaschke, Christina Caroline; Bertino, Giulia; McCaul, James; Grau, Juan J.; Bree, Remco de; Serša, Gregor; Occhini, Antonio; Groselj, Aleš; Langdon, Cristóbal; Heuveling, Derrek A.; Čemažar, Maja; Strojan, Primož; Leemans, C. René; Benazzo, Marco; Terlizzi, Francesca de; Wessel, Irene; Gehl, Julie

doi:10.1016/j.ejca.2017.10.008

Cited by 80 publications

(77 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The overall appearance of the post‐treatment mucosal reaction to calcium electroporation with swelling and necrosis was similar to the one shown with electrochemotherapy . Regarding tumor response, a recent trial using electrochemotherapy on 43 patients showed an objective response rate (CR + PR) of 56% with complete response in 19% . Currently, we cannot compare tumor responses between these two electroporation modalities since the calcium data is based on only six patients.…”

Section: Discussionsupporting

confidence: 53%

“…Based on our previous experience with ECT on mucosal head and neck cancers and the current knowledge on calcium electroporation, we wanted to test the safety of using calcium electroporation on mucosal, head and neck cancers. The use of calcium instead of a chemotherapeutic agent would offer advantages, in particular for readiness of use and simplicity of treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Calcium electroporation for recurrent head and neck cancer: A clinical phase I study

Plaschke

Gehl

Johannesen

et al. 2019

Laryngoscope Investig Oto

Self Cite

View full text Add to dashboard Cite

Background Calcium electroporation is a novel cancer treatment, which combines temporary cell permeability from electroporation with a high influx of calcium intracellularly resulting in cancer cell necrosis. Methods A phase I trial performing calcium electroporation on 6 patients suffering from recurrent head and neck cancer. In general anesthesia, intratumoral calcium injections were followed by electroporation. Safety was monitored by adverse events registration, serum Ca 2+ , ECG, and pain scores. Tumor response was measured on PET/MRI scans. Results Procedures were performed without complications. No serious adverse events, signs of hypercalcemia, or cardiac arrhythmias were observed. Two months post‐treatment tumor responses on MRI: three partial responses, one stable disease, and two progression. Responses on PET: one partial metabolic disease, four with stable metabolic disease, and one not evaluable. One patient was without clinical evidence of disease after 12 months of observation. Conclusion Calcium electroporation is feasible and safe in head and neck tumors. Clinical responses were observed in three of six patients, warranting further studies. Level of Evidence Level 4

show abstract

Section: Discussionsupporting

confidence: 53%

Section: Introductionmentioning

confidence: 99%

Calcium electroporation for recurrent head and neck cancer: A clinical phase I study

Plaschke

Gehl

Johannesen

et al. 2019

Laryngoscope Investig Oto

Self Cite

View full text Add to dashboard Cite

show abstract

“…The most recent study being the European collaboration (EURECA), in which the first 13 patients also were included. A total of 43 patients were treated for a recurrence with an objective response of 56% . Other studies treating recurrent head and neck carcinomas have reported objective tumor response in 10 out of 12 patients (Allegretti and Panje) and in 7 out of 12 patients (Campana et al).…”

Section: Discussionmentioning

confidence: 99%

“…The first 13 patients included in this study were also part of the European collaboration, but each patient only received electrochemotherapy once. The study was recently published …”

Section: Methodsmentioning

confidence: 99%

The DAHANCA 32 study: Electrochemotherapy for recurrent mucosal head and neck cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background Electrochemotherapy is an established treatment for cutaneous tumors. This study aimed at determining efficacy of electrochemotherapy in recurrent head and neck cancer. Methods Phase II clinical trial in patients with recurrent head and neck carcinomas with no curative treatment options. Electrochemotherapy was performed under general anesthesia. Primary endpoint was tumor response (CT scanning) evaluated at week 8. Secondary endpoints included biopsy results, MRI and fluorodeoxyglucose‐positron emission tomography scanning, safety, toxicity, pain score, and quality‐of‐life questionnaires. Results Of 26 patients treated, 5 (19%) achieved complete response, 10 (39%) partial response, resulting in an objective response of 58%. Two responders remain without recurrence. No serious adverse events occurred during treatment. Four events occurred posttreatment: one bleeding episode, two episodes with mucosal swelling, and one patient died due to disease progression. Conclusion Electrochemotherapy is efficient against local recurrence of head and neck cancer with an overall response rate of 58%.

show abstract

“…Once inside the cell, the cytotoxicity of bleomycin is increased by up to 3–700‐fold and the tumor cell enters apoptosis . The largest study published to date using electrochemotherapy on recurrent mucosal head and neck malignancies is a European collaboration treating 43 patients . The study demonstrated an overall objective tumor response of 56%.…”

Section: Electrochemotherapymentioning

confidence: 99%

An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome

Andreasen

Kiss

Mikkelsen

et al. 2019

APMIS

Self Cite

View full text Add to dashboard Cite

The head and neck region harbor numerous specialized tissues of all lineages giving rise to a plethora of different malignancies. In recent years, new types and subtypes of cancer has been described here due to the recognition of their histological and molecular characteristics. Some have been formally accepted in the most recent classifications from the World Health Organization (WHO) and American Joint Committee on Cancer (AJCC) as distinct diseases due to characteristics in clinical presentation, outcome, and treatment. In particular, this applies to malignancies of the salivary gland, sinonasal tract, and oropharynx. In this overview, we present the most recent developments in the classification, histopathological characteristics, and molecular features of head and neck cancer. The clinical and radiological characteristics, outcome, and treatment options including perspectives for targeted therapies, are discussed.

show abstract

European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers

Cited by 80 publications

References 32 publications

Calcium electroporation for recurrent head and neck cancer: A clinical phase I study

Calcium electroporation for recurrent head and neck cancer: A clinical phase I study

The DAHANCA 32 study: Electrochemotherapy for recurrent mucosal head and neck cancer

An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome

Contact Info

Product

Resources

About